Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Construct optimization for AAV-mediated human α-syn overexpression, and validation across research settings: Development of a shared tool for the research community.

Journal of Parkinson's disease·2026
Same author

The DNA/RNA autophagy protein SIDT2 as a novel neuropathological hallmark in Huntington disease.

Brain pathology (Zurich, Switzerland)·2026
Same author

Administration of a barcoded AAV capsid library to the putamen of non-human primates identifies variants with efficient retrograde transport.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Differential effects of overexpression of mutant huntingtin and TDP-43 in agouti-related protein neurons in the arcuate nucleus of the hypothalamus in mice.

Acta neuropathologica communications·2025
Same author

PARKIN protein-deficient iPSC line (FINi006-A) from an early-onset Parkinson's disease female patient.

Stem cell research·2025
Same author

Dopamine and cortical neurons with different Parkinsonian mutations show variation in lysosomal and mitochondrial dysfunction.

NPJ Parkinson's disease·2025

Related Experiment Video

Updated: Jun 8, 2026

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies
12:13

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies

Published on: July 11, 2019

Gene therapy for dopamine replacement.

Tomas Björklund1, Erik Ahlm Cederfjäll, Deniz Kirik

  • 1Brain Repair and Imaging in Neural Systems, Department of Experimental Medical Science, Lund University, Lund, Sweden. tomas.bjorklund@med.lu.se

Progress in Brain Research
|October 5, 2010
PubMed
Summary

Gene therapy offers a novel approach to dopamine replacement for Parkinson's disease (PD). This chapter details viral vector-mediated enzyme replacement strategies, including early trials for PD patients.

More Related Videos

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Related Experiment Videos

Last Updated: Jun 8, 2026

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies
12:13

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies

Published on: July 11, 2019

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Area of Science:

  • Neuroscience
  • Gene Therapy
  • Parkinson's Disease Research

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder characterized by dopamine deficiency.
  • Current treatments like l-DOPA have limitations, prompting the development of advanced therapies.
  • Three major advancements in dopamine replacement for PD include agonists, ex vivo gene transfer, and in vivo gene therapy.

Purpose of the Study:

  • To describe the principles of viral vector-mediated enzyme replacement for PD.
  • To review enzymes in dopamine synthesis and their regulation.
  • To discuss early experimental gene therapy work and clinical trials in PD.

Main Methods:

  • Focus on viral vector-mediated enzyme replacement strategies.
  • Examination of enzymes critical for dopamine synthesis.
  • Review of different viral vector types and transgene selection in experimental models.
  • Analysis of early-phase clinical trial data in PD patients.

Main Results:

  • Viral vector-mediated enzyme replacement is a promising therapeutic avenue for PD.
  • Understanding dopamine synthesis pathways is crucial for effective gene therapy.
  • Early clinical trials of in vivo gene therapy for PD are underway.

Conclusions:

  • In vivo gene therapy represents a significant advancement in treating Parkinson's disease.
  • Further research and clinical trials are essential to optimize viral vector-mediated enzyme replacement therapies.
  • This approach holds potential for long-term dopamine restoration in PD patients.